Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment
Open accessThe DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment (TME) in breast cancer comprises local factors, cancer cells, immune cells and stromal cells of the local and distant tissues. The interaction between cancer cells and their microenvironment plays important roles in tumor proliferation, propagation and response to therapies. There is increasing research in exploring and manipulating the non-cancerous components of the TME for breast cancer treatment. As the TME is now increasingly recognized as a treatment target, its pathologic assessment has become a critical component of breast cancer management. The latest WHO classification of tumors of the breast listed stromal response pattern/fibrotic focus as a prognostic factor and includes recommendations on the assessment of tumor infiltrating lymphocytes and PD-1/PD-L1 expression, with therapeutic implications. This review dissects the TME of breast cancer, describes pathologic assessment relevant for prognostication and treatment decision, and details therapeutic options that interacts with and/or exploits the TME in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“When engaged by PD-L1, PD1 inhibits T-cell activation and is known to be a major contributor of immune resistance in the TME [38].”
BackgroundCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996 · cited 1×
“Upon irradiation, DNA/micronuclei are released to cytosol and they activate the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, resulting in the production of type I interferons [76].”
BackgroundCirculating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593 · cited 1×
“High levels of circulating tumor cells (CTC) are associated with an unfavorable prognosis in patients with metastatic breast cancer [61,62].”
BackgroundAtezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 1×
“Conversely, M2 macrophages, the alternatively activated phenotype, are activated by Th2 cytokines (IL4, IL10 and IL-13) and are pro-tumor in nature [32].”
BackgroundPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223 · cited 1×
“This immunogenic cell death (ICD) of cancer cells can change towards a more immunostimulatory TME cytokine profile [75].”
BackgroundSalgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×
“Common chemotherapeutic agents used in neoadjuvant and primary chemotherapies, such as taxanes, anthracyclines and anti-HER2 monoclonal antibodies can directly induce immunostimulatory effects of tumor cell killing through DC activation [74].”
BackgroundCCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“For example, after radiation, breast cancer cells produce CCL2 [82], which stimulates TAM recruitment [83] and breast cancer cells to modulate tumor survival and invasion [84].”
BackgroundSelf-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3110 · Cited by 2,237 · cited 1×
“An acidic microenvironment confers pro-tumor effects by facilitating an ECM favoring tumor invasion, inhibiting transcellular uptake of chemotherapeutic agents [58].”
BackgroundDenkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157 · cited 2×
“Although a high TIL level in breast cancers is associated with unfavorable subtypes [8–11], there is a positive association with a good prognosis and better response to NAC, particularly in TNBCs and HER2 + breast cancers [9,109,133,134].”
BackgroundThe Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 2×
“Lysyl oxidase (LOX) and integrins are also implicated in radiation-induced fibrosis [73,99].”
BackgroundSingle-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., & Detmar, M. (2001) · Nature Medicine · doi:10.1038/84643 · Cited by 1,733 · cited 1×
“VEGF-C overexpressing breast cancers are associated with lymphatic vessels invasion, lymph node metastasis and shorter disease-free survival [52,53].”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 2×
“In clinical breast cancers, an inverse association of CAF and CD8 T-cells can be demonstrated [47].”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., & Kolesnick, R. (2003) · Science · doi:10.1126/science.1082504 · Cited by 1,593 · cited 1×
“Although there is theoretical benefit in disrupting nutrient supply to tumor cells [102], radiation actually causes more reduction in therapeutic efficacy and hence jeopardizing prognosis.”
BackgroundExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589 · cited 1×
“Given the clinical success of immune checkpoint blockade, much attention has been put on immune checkpoint molecules, especially programmed cell death protein 1 (PD1), and its ligand PD-L1, which is expressed by cancer cells and immune cells (B-cells, T-cells, DC, and macrophages) [36,37].”
BackgroundCD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260 · cited 1×
“Local radiation may contribute to the tumor cell elimination at non-irradiated metastatic sites as locally activated DC can migrate and cross-prime T-cells in lymph nodes to induce a systemic antitumor immunity (the abscopal effect) [77].”
BackgroundImmune Regulatory Function of B Cells
Mauri, C., & Bosma, A. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074934 · Cited by 1,249 · cited 1×
“Regulatory B-cells (Bregs) express inhibitory molecules such as programmed cell death-ligand 1 (PD-L1) and FAS ligands (FasL) along with the production of anti-inflammatory cytokines such as IL-10, TGF-β, and IL-35 that inhibit immune responses [27].”
BackgroundNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer
Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074 · cited 1×
“TAM can further induce angiogenesis and secrete immunosuppressive mediators like IL-10 and TGF-b, which further promote a radioresistant phenotype [85].”
BackgroundSelf-citationCD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070 · cited 1×
“Follicular helper T-cells (Tfh) play important roles in antigen specific B-cell maturation, promoting local memory cell differentiation and supporting the development of tertiary lymphoid organ thus enhancing local anti-tumor immune response [18,19].”
BackgroundCombining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053 · cited 1×
“, VCAM-1 and ICAM-1 on endothelial cells, promoting migration of lymphocytes into the tumor parenchyma [79,80].”
BackgroundSaltz, J., Gupta, R., Hou, L., Kurc, T., Singh, P., Nguyen, V., Samaras, D., Shroyer, K. R., Zhao, T., Batiste, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.086 · Cited by 1,027
Self-citationRadiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970 · cited 1×
“CTLA-4, a cell surface receptor found on activated T-cells that induces anergy by competitive inhibition of CD28 receptors, is another example of a targetable immune checkpoint in other human cancers [41].”
BackgroundRadiotherapy induces responses of lung cancer to CTLA-4 blockade
Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928 · cited 2×
“Other molecules crucial to anti-tumor immunity including MHC class I and MIC A/B, and these are also upregulated by radiation [81].”
BackgroundThe effects of extracellular pH on immune function
Lardner, A. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.4.522 · Cited by 864 · cited 1×
“Overall, hypoxia and acidosis confer an adaptive survival advantage to resistant tumor clones, resulting in clonal selection; they also hamper the cytotoxic effects of neutrophils and lymphocytes by limiting ROS generation, reducing cellular motility and creating a hostile extracellular environment [59].”
BackgroundBiological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828
Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., Lindgren, D., Pekar, G., Karlsson, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07582-3 · Cited by 826 · cited 2×
“Among them, vascular CAF and matrix CAF signatures have prognostic power [48].”
BackgroundExosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
Boelens, M. C., Wu, T. J., Nabet, B. Y., Xu, B., Qiu, Y., Yoon, T., Azzam, D. J., Twyman-Saint Victor, C., Wiemann, B. Z., Ishwaran, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.051 · Cited by 806 · cited 1×
“STAT1, via juxtacrine NOTCH3 pathway, mediates treatment resistance in breast cancer [98].”
BackgroundAssociation between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali, H. R., Provenzano, E., Dawson, S.-J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 774
Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P., & Biragyn, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4316 · Cited by 684 · cited 10×
“These cytokines and chemokines attract Tregs and sustain a pro-tumor TME [106,107].”
BackgroundInfluentialMonteran, L., & Erez, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01835 · Cited by 675
Radiation-induced cell death mechanisms
Eriksson, D., & Stigbrand, T. (2010) · Tumor Biology · doi:10.1007/s13277-010-0042-8 · Cited by 666 · cited 1×
“Radiotherapy induces double strand DNA breaks, resulting in cell death mainly through mitotic catastrophe and less commonly by apoptosis and cellular senescence [72].”
BackgroundAdams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 637
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Farmer, P., Bonnefoi, H., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M., Campone, M., Brain, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.1908 · Cited by 623
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602 · cited 1×
“Cytokines/chemokines and growth factors secreted by tumor cells are believed to induce receptive changes favoring tumor seeding [63,64].”
BackgroundGraham, K., & Unger, E. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s140462 · Cited by 584
Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578
LOX-Mediated Collagen Crosslinking Is Responsible for Fibrosis-Enhanced Metastasis
Cox, T. R., Bird, D., Baker, A.-M., Barker, H. E., Ho, M. W.-Y., Lang, G., & Erler, J. T. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2233 · Cited by 571 · cited 5×
“In addition, the treatment efficacy in targeting ECM remodeling enzymes (MMP and LOX inhibitors) [211,212] is supported by strong pre-clinical data.”
BackgroundInfluentialMacrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Barcellos‐Hoff, M. H., & Ravani, S. A. (2000) · PubMed · Cited by 536
Role of the Tumor Microenvironment in Breast Cancer
Soysal, S. D., Tzankov, A., & Muenst, S. E. (2015) · Pathobiology · doi:10.1159/000430499 · Cited by 510 · cited 3×
“The regional compartment refers to the interplay between tumor cells and the adjacent cells in the stroma, particularly at the infiltrating edge, involving stromal fibroblasts, myoepithelial cells, adipocytes and endothelial and vascular/lymphatic endothelial cells [1,5].”
BackgroundKodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Winer, E. P., Lipatov, O., Im, S.-A., Goncalves, A., Muñoz-Couselo, E., Lee, K. S., Schmid, P., Tamura, K., Testa, L., Witzel, I., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30754-3 · Cited by 489
Leukocyte composition of human breast cancer
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 479 · cited 10×
“Given the clinical success of immune checkpoint blockade, much attention has been put on immune checkpoint molecules, especially programmed cell death protein 1 (PD1), and its ligand PD-L1, which is expressed by cancer cells and immune cells (B-cells, T-cells, DC, and macrophages) [36,37].”
BackgroundInfluentialHollern, D. P., Xu, N., Thennavan, A., Glodowski, C., Garcia-Recio, S., Mott, K. R., He, X., Garay, J. P., Carey-Ewend, K., Marron, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.028 · Cited by 478 · cited 1×
“Their anti-tumor activities are mediated by the recognition of tumor-specific antigens and antibody production or antigen presenting cell (APC) function [23,24].”
BackgroundNakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478
Microvessel Density as a Prognostic Factor in Women with Breast Cancer
Uzzan, B., Nicolas, P., Cucherat, M., & Perret, G.-Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1957 · Cited by 468
Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer
Treilleux, I., Blay, J.-Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J.-P., Bremond, A., Goddard, S., Pin, J.-J., Barthelemy-Dubois, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0684 · Cited by 460 · cited 3×
“High levels of both DC types are accompanied by increased T-cell infiltration [30,184].”
BackgroundInfluentialCazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C.-L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05220-6 · Cited by 437
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 434
Radiation Enhances Regulatory T Cell Representation
Kachikwu, E. L., Iwamoto, K. S., Liao, Y.-P., DeMarco, J. J., Agazaryan, N., Economou, J. S., McBride, W. H., & Schaue, D. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.09.034 · Cited by 429 · cited 1×
“Likewise, Tregs, with their activation of PI3K/AKT pathway, are more radioresistant than other T-cell subtypes, and preferentially survive after radiation [88].”
BackgroundTumor-associated macrophages in breast cancer: Innocent bystander or important player?
Qiu, S.-Q., Waaijer, S. J. H., Zwager, M. C., de Vries, E. G. E., van der Vegt, B., & Schröder, C. P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.010 · Cited by 425 · cited 2×
“M1 macrophages, the classically activated phenotype, are stimulated by Th1 cytokines (IFN-γ and tumor necrosis factor (TNF)) and in turn exert anti-tumor effects by producing reactive nitrogen and oxygen species (ROS) and releasing pro-inflammation cytokines [31].”
BackgroundHumoral immunity, inflammation and cancer
Tan, T.-T., & Coussens, L. M. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.001 · Cited by 417 · cited 1×
“The T helper type 2 (Th2) and type 17 (Th17) cells have more varied roles in breast cancer progression [16,17].”
BackgroundCD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
Nelson, B. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001323 · Cited by 416 · cited 1×
“B-cells can be found in close proximity with T-cells particularly at tertiary lymphoid structures (TLS) in TME [25], and their presence is considered a favorable prognostic factor [12,25].”
BackgroundHarrell, M. I., Iritani, B. M., & Ruddell, A. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060761 · Cited by 388
Rugo, H. S., Delord, J.-P., Im, S.-A., Ott, P. A., Piha-Paul, S. A., Bedard, P. L., Sachdev, J., Tourneau, C. L., van Brummelen, E. M. J., Varga, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3452 · Cited by 376
Jekyll and Hyde: the role of the microenvironment on the progression of cancer
Allen, M., & Louise Jones, J. (2011) · The Journal of Pathology · doi:10.1002/path.2803 · Cited by 375
Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Saatci, O., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, O., Banister, C. E., Sikirzhytski, V., Tokat, U. M., Aykut, G., Ansari, S. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16199-4 · Cited by 368
Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium.
Hallahan, D. E., Kuchibhotla, J., & Wyble, C. W. (1996) · PubMed · Cited by 358
West, N. R., Milne, K., Truong, P. T., Macpherson, N., Nelson, B. H., & Watson, P. H. (2011) · Breast Cancer Research · doi:10.1186/bcr3072 · Cited by 356
Immunological differences between primary and metastatic breast cancer
Szekely, B., Bossuyt, V., Li, X., Wali, V. B., Patwardhan, G. A., Frederick, C., Silber, A., Park, T., Harigopal, M., Pelekanou, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy399 · Cited by 354 · cited 1×
“Moreover, a substantially lower TIL count, accompanying by an increase in immunosuppressive gene signature was found in breast cancer metastases compared to the primary tumors [68].”
BackgroundTumor-infiltrating B cells signal functional humoral immune responses in breast cancer
Garaud, S., Buisseret, L., Solinas, C., Gu-Trantien, C., de Wind, A., Van den Eynden, G., Naveaux, C., Lodewyckx, J.-N., Boisson, A., Duvillier, H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129641 · Cited by 347 · cited 10×
“Given the clinical success of immune checkpoint blockade, much attention has been put on immune checkpoint molecules, especially programmed cell death protein 1 (PD1), and its ligand PD-L1, which is expressed by cancer cells and immune cells (B-cells, T-cells, DC, and macrophages) [36,37].”
BackgroundInfluentialTumor-Associated Neutrophils in Cancer: Going Pro
Wu, L., Saxena, S., Awaji, M., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11040564 · Cited by 337 · cited 1×
“biologic features of the tumor cells and the tumor infiltrating inflammatory cells including lymphocytes, plasma cells, dendritic cells, macrophages and neutrophils [3,4].”
BackgroundMarciscano, A. E., Ghasemzadeh, A., Nirschl, T. R., Theodros, D., Kochel, C. M., Francica, B. J., Muroyama, Y., Anders, R. A., Sharabi, A. B., Velarde, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3427 · Cited by 335 · cited 1×
“In animal model, tumor resident T-cells are more resistant to radiotherapy than those found in lymph node [86,87].”
BackgroundAspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E. C., Su, D., Marches, F., Banchereau, J., & Palucka, A. K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061120 · Cited by 334 · cited 1×
“The T helper type 2 (Th2) and type 17 (Th17) cells have more varied roles in breast cancer progression [16,17].”
BackgroundMuenst, S., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., & Gillanders, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2581-3 · Cited by 334 · cited 1×
“PD-1 + TIL are associated with a worse overall survival in breast cancer patients [11,39], and high PD-L1 expression is seen in high TIL, high grade, hormone receptor negative, HER2 overexpressed and triple negative breast cancers (TNBCs) [40].”
BackgroundGupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322
Seo, A. N., Lee, H. J., Kim, E. J., Kim, H. J., Jang, M. H., Lee, H. E., Kim, Y. J., Kim, J. H., & Park, S. Y. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.634 · Cited by 317
Ladoire, S., Arnould, L., Apetoh, L., Coudert, B., Martin, F., Chauffert, B., Fumoleau, P., & Ghiringhelli, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4491 · Cited by 310
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
Vonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D., Soulieres, D., Dorazio, P., Trosko, J. A., Rüter, J., Mariani, G. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0505 · Cited by 301
An Attempt to Polarize Human Neutrophils Toward N1 and N2 Phenotypes in vitro
Ohms, M., Möller, S., & Laskay, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00532 · Cited by 299 · cited 1×
“N1 proinflammatory and anti-tumor TAN are generated by IFN-γ and IFN-β exposure, whereas N2 anti-inflammatory and pro-tumor TAN are induced by TGF-β exposure [33,34].”
Background(1926) · The American Journal of Surgery · doi:10.1016/s0002-9610(26)90068-8 · Cited by 293
Soria, G., Ofri-Shahak, M., Haas, I., Yaal-Hahoshen, N., Leider-Trejo, L., Leibovich-Rivkin, T., Weitzenfeld, P., Meshel, T., Shabtai, E., Gutman, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-130 · Cited by 275
The prognostic significance of lymphovascular invasion in invasive breast carcinoma
Rakha, E. A., Martin, S., Lee, A. H. S., Morgan, D., Pharoah, P. D. P., Hodi, Z., MacMillan, D., & Ellis, I. O. (2012) · Cancer · doi:10.1002/cncr.26711 · Cited by 271
Mechanisms of osteolytic bone metastases in breast carcinoma
K�k�nen, S.-M., & Mundy, G. R. (2003) · Cancer · doi:10.1002/cncr.11132 · Cited by 269
Tumour-infiltrating macrophages and clinical outcome in breast cancer
Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200355 · Cited by 268
Lymphangiogenesis and lymphatic metastasis in breast cancer
Ran, S., Volk, L., Hall, K., & Flister, M. J. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2009.11.003 · Cited by 250 · cited 1×
“Tumor-containing lymph nodes show altered immune cell composition (higher Treg density) and structure (lymph node enlargement and lymphangiogenesis) compared to native, benign sentinel lymph nodes [6,65,66].”
BackgroundJohansson, S., Svensson, H., & Denekamp, J. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02743-2 · Cited by 236
Choi, W. W. L., Lewis, M. M., Lawson, D., Yin-Goen, Q., Birdsong, G. G., Cotsonis, G. A., Cohen, C., & Young, A. N. (2005) · Modern Pathology · doi:10.1038/modpathol.3800253 · Cited by 230 · cited 4×
“Intratumoral and stromal VEGF expressions correlated with microvascular density [5].”
BackgroundInfluentialTumor-reprogrammed resident T cells resist radiation to control tumors
Arina, A., Beckett, M., Fernandez, C., Zheng, W., Pitroda, S., Chmura, S. J., Luke, J. J., Forde, M., Hou, Y., Burnette, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11906-2 · Cited by 229 · cited 1×
“In animal model, tumor resident T-cells are more resistant to radiotherapy than those found in lymph node [86,87].”
BackgroundCollette, S., Collette, L., Budiharto, T., Horiot, J.-C., Poortmans, P. M., Struikmans, H., Van den Bogaert, W., Fourquet, A., Jager, J. J., Hoogenraad, W., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.032 · Cited by 224
Burugu, S., Asleh-Aburaya, K., & Nielsen, T. O. (2017) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 222 · cited 1×
“TAN can reduce CD8 proliferation and recruit immunosuppressive cells in TME in breast cancer mouse models, but their effects in human patients are unclear [35].”
BackgroundPD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalves, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 221
β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts
Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., & Bissell, M. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6390 · Cited by 220
Prognostic value of tumor‐infiltrating dendritic cells expressing CD83 in human breast carcinomas
Iwamoto, M., Shinohara, H., Miyamoto, A., Okuzawa, M., Mabuchi, H., Nohara, T., Gon, G., Toyoda, M., & Tanigawa, N. (2003) · International Journal of Cancer · doi:10.1002/ijc.10915 · Cited by 219
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 216
Hypoxia in Breast Cancer: Pathogenesis, Characterization and Biological/Therapeutic Implications
Vaupel, P., Briest, S., & Hockel, M. (2002) · Wiener Medizinische Wochenschrift · doi:10.1046/j.1563-258x.2002.02032.x · Cited by 209 · cited 3×
“Low oxygen pressure and poor perfusion impair the effects of traditional chemotherapy and radiotherapy [57].”
BackgroundNovel approaches to target the microenvironment of bone metastasis
Hofbauer, L. C., Bozec, A., Rauner, M., Jakob, F., Perner, S., & Pantel, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00499-9 · Cited by 207 · cited 1×
“Osteoclastic bone resorption, in turn, releases growth factors including TGF-β that stimulate cancer cell proliferation and perpetuate the osteolytic vicious cycle [7,70,71].”
BackgroundThe lymph node microenvironment and its role in the progression of metastatic cancer
Pereira, E. R., Jones, D., Jung, K., & Padera, T. P. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.01.008 · Cited by 204 · cited 2×
“The metastatic compartment refers to host cells at lymph nodes and distant organs as metastatic sites, forming new TME [6,7].”
BackgroundNúñez, N. G., Tosello Boari, J., Ramos, R. N., Richer, W., Cagnard, N., Anderfuhren, C. D., Niborski, L. L., Bigot, J., Meseure, D., De La Rochere, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17046-2 · Cited by 199 · cited 1×
“Tumor-containing lymph nodes show altered immune cell composition (higher Treg density) and structure (lymph node enlargement and lymphangiogenesis) compared to native, benign sentinel lymph nodes [6,65,66].”
BackgroundFang, W. B., Jokar, I., Zou, A., Lambert, D., Dendukuri, P., & Cheng, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365999 · Cited by 197 · cited 1×
“For example, after radiation, breast cancer cells produce CCL2 [82], which stimulates TAM recruitment [83] and breast cancer cells to modulate tumor survival and invasion [84].”
BackgroundPlasmacytoid Dendritic Cells: Physiologic Roles and Pathologic States
Jegalian, A. G., Facchetti, F., & Jaffe, E. S. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181bb6bc2 · Cited by 193
Donlon, N. E., Power, R., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 189
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Park, Y. H., Lal, S., Lee, J. E., Choi, Y.-L., Wen, J., Ram, S., Ding, Y., Lee, S.-H., Powell, E., Lee, S. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19933-0 · Cited by 186
Sharma, S. K., Chintala, N. K., Vadrevu, S. K., Patel, J., Karbowniczek, M., & Markiewski, M. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403215 · Cited by 184 · cited 10×
“N1 proinflammatory and anti-tumor TAN are generated by IFN-γ and IFN-β exposure, whereas N2 anti-inflammatory and pro-tumor TAN are induced by TGF-β exposure [33,34].”
BackgroundInfluentialImmune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J., & Collins, D. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 182
Molecular Pathways: Connecting Fibrosis and Solid Tumor Metastasis
Cox, T. R., & Erler, J. T. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1059 · Cited by 175
Lymphangiogenesis and cancer metastasis
Mumprecht, V., & Detmar, M. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00834.x · Cited by 171 · cited 1×
“Likewise, VEGF-C, which induces lymphangiogenesis in lymphatic endothelial cells, is detected in breast cancers [51].”
BackgroundPontiggia, O., Sampayo, R., Raffo, D., Motter, A., Xu, R., Bissell, M. J., de Kier Joffé, E. B., & Simian, M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1766-x · Cited by 166
Dendritic Cells and Tumor Microenvironment: A Dangerous Liaison
Fricke, I., & Gabrilovich, D. I. (2006) · Immunological Investigations · doi:10.1080/08820130600803429 · Cited by 165
Yamaguchi, R., Tanaka, M., Yano, A., Tse, G. M.-K., Yamaguchi, M., Koura, K., Kanomata, N., Kawaguchi, A., Akiba, J., Naito, Y., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.013 · Cited by 164
Self-citationEndothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Tavora, B., Reynolds, L. E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D. M., Wong, P.-P., Alexopoulou, A., Elia, G., et al. (2014) · Nature · doi:10.1038/nature13541 · Cited by 163
Lee, H. J., Park, I. A., Song, I. H., Shin, S.-J., Kim, J. Y., Yu, J. H., & Gong, G. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203089 · Cited by 162
Bachelot, T., Filleron, T., Bieche, I., Arnedos, M., Campone, M., Dalenc, F., Coussy, F., Sablin, M.-P., Debled, M., Lefeuvre-Plesse, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01189-2 · Cited by 161
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer
Radisky, E. S., Raeeszadeh‐Sarmazdeh, M., & Radisky, D. C. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26185 · Cited by 160
Generali, D., Bates, G., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., Bersiga, A., Allevi, G., Milani, M., Aguggini, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1507 · Cited by 160
Brown, J. R., Wimberly, H., Lannin, D. R., Nixon, C., Rimm, D. L., & Bossuyt, V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1622 · Cited by 159
Heindl, A., Sestak, I., Naidoo, K., Cuzick, J., Dowsett, M., & Yuan, Y. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx137 · Cited by 156
Breast Carcinoma–Associated Fibroblasts and Their Counterparts Display Neoplastic-Specific Changes
Hawsawi, N. M., Ghebeh, H., Hendrayani, S., Tulbah, A. M., Al-Eid, M., Al‐Tweigeri, T., Ajarim, D. S., Alaiya, A. A., Dermime, S., & Aboussekhra, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0192 · Cited by 155 · cited 1×
“Compared to their normal counterparts, CAF display a higher proliferative index and defects in tumor suppressor proteins [42].”
BackgroundDoherty, G. J., Tempero, M., & Corrie, P. G. (2018) · Future Oncology · doi:10.2217/fon-2017-0338 · Cited by 153
Rugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiß, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M. M., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab108 · Cited by 153
Mendoza, M. S., & Morales‐Montor, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00348 · Cited by 149
Mohammed, Z. M. A., Going, J. J., Edwards, J., Elsberger, B., & McMillan, D. C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.493 · Cited by 148
Tsai, K. K. C., Chuang, E. Y.-Y., Little, J. B., & Yuan, Z.-M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0703 · Cited by 145 · cited 2×
“Radiation induces a senescence-like phenotype and MMP production in fibroblasts, leading to extracellular collagen deposition [91].”
BackgroundPresence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis
Trapp, E., Janni, W., Schindlbeck, C., Jückstock, J., Andergassen, U., de Gregorio, A., Alunni-Fabbroni, M., Tzschaschel, M., Polasik, A., Koch, J. G., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy152 · Cited by 140 · cited 1×
“High levels of circulating tumor cells (CTC) are associated with an unfavorable prognosis in patients with metastatic breast cancer [61,62].”
BackgroundClinical significance of vascular endothelial growth factor‐C (VEGF‐C) in breast cancer
Kinoshita, J., Kitamura, K., Kabashima, A., Saeki, H., Tanaka, S., & Sugimachi, K. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010692132669 · Cited by 140 · cited 1×
“VEGF-C overexpressing breast cancers are associated with lymphatic vessels invasion, lymph node metastasis and shorter disease-free survival [52,53].”
BackgroundImmunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Bertucci, F., & Gonçalvès, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0627-0 · Cited by 138 · cited 1×
“PD-1 + TIL are associated with a worse overall survival in breast cancer patients [11,39], and high PD-L1 expression is seen in high TIL, high grade, hormone receptor negative, HER2 overexpressed and triple negative breast cancers (TNBCs) [40].”
BackgroundTumor microenvironment-mediated chemoresistance in breast cancer
velaei, K., Samadi, N., Barazvan, B., & Soleimani Rad, J. (2016) · The Breast · doi:10.1016/j.breast.2016.09.002 · Cited by 138
Sansone, P., Berishaj, M., Rajasekhar, V. K., Ceccarelli, C., Chang, Q., Strillacci, A., Savini, C., Shapiro, L., Bowman, R. L., Mastroleo, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2129 · Cited by 137
Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities
Wang, Z., Tang, Y., Tan, Y., Wei, Q., & Yu, W. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0362-2 · Cited by 135 · cited 1×
“In other human cancers, CAF conferred radioprotective effects to tumor cells through platelet derived growth factor-AA and IGF binding protein2, - 4 and - 6 (resistance to radiation-induced cell death) and CXCL1 (enhancing DNA damage repair) [97].”
BackgroundPeyrol, S., Raccurt, M., Gérard, F., Gleyzal, C., Grimaud, J.-A., & Sommer, P. (1997) · Europe PMC (PubMed Central) · Cited by 135
Priming the ‘Soil’ for Breast Cancer Metastasis: The Pre-Metastatic Niche
Psaila, B., Kaplan, R. N., Port, E. R., & Lyden, D. (2007) · Breast Disease · doi:10.3233/bd-2007-26106 · Cited by 133
Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Lee, H. J., Seo, J. Y., Ahn, J., Ahn, S. H., & Gong, G. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.1.32 · Cited by 132
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy
Hong, S. P., Chan, T. E., Lombardo, Y., Corleone, G., Rotmensz, N., Bravaccini, S., Rocca, A., Pruneri, G., McEwen, K. R., Coombes, R. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11721-9 · Cited by 129
Soumelis, V., & Liu, Y. J. (2006) · European Journal of Immunology · doi:10.1002/eji.200636026 · Cited by 128
Hyaluronan, Cancer-Associated Fibroblasts and the Tumor Microenvironment in Malignant Progression
McCarthy, J. B., El-Ashry, D., & Turley, E. A. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00048 · Cited by 127
Soon, P. S. H., Kim, E., Pon, C. K., Gill, A. J., Moore, K., Spillane, A. J., Benn, D. E., & Baxter, R. C. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0227 · Cited by 127 · cited 1×
“High level of CXCL12 expressed by CAF [93] via signaling through its receptor CXCR4 can support tumor cell stemness in breast cancer [94] and contribute to radioresistance.”
BackgroundAngiogenesis and Breast Cancer
Longatto‐Filho, A., Lopes, J. M., & Schmitt, F. C. (2010) · Journal of Oncology · doi:10.1155/2010/576384 · Cited by 127
Varadan, V., Gilmore, H., Miskimen, K. L. S., Tuck, D., Parsai, S., Awadallah, A., Krop, I. E., Winer, E. P., Bossuyt, V., Somlo, G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2021 · Cited by 119
Role of cancer-associated fibroblasts in breast cancer development and prognosis
Aboussekhra, A. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.113362aa · Cited by 119 · cited 1×
“Through the effects of soluble factors and matrix altering enzymes such as vascular endothelial growth factor A and TGF-β, and matrix metalloproteinases (MMP), CAF induce tumor progression by promoting angiogenesis, tumor growth and invasion [43].”
BackgroundEmerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Dees, S., Ganesan, R., Singh, S., & Grewal, I. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0385 · Cited by 118
Lespagnard, L., Gancberg, D., Rouas, G., Leclercq, G., Somerhausen, N. D. S.-A., Leo, A. D., Piccart, M. J., Verhest, A. P., & Larsimont, D. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990621)84:3<309::aid-ijc19>3.0.co;2-3 · Cited by 118
Peiris-Pagès, M., Sotgia, F., & Lisanti, M. P. (2015) · Oncotarget · doi:10.18632/oncotarget.3828 · Cited by 115
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Triulzi, T., Forte, L., Regondi, V., Modica, M. D., Ghirelli, C., Carcangiu, M. L., Sfondrini, L., Balsari, A., & Tagliabue, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512942 · Cited by 113
Mueller, K. L., Madden, J. M., Zoratti, G. L., Kuperwasser, C., List, K., & Boerner, J. L. (2012) · Breast Cancer Research · doi:10.1186/bcr3224 · Cited by 111
Tsang, J. Y., AU, W., Lo, K.-Y., Ni, Y., Hlaing, T., Hu, J., Chan, S., Chan, K.-F., Cheung, S., & Tse, G. M.-K. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4095-2 · Cited by 111
Self-citationTyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells
Wen, B., Deutsch, É., Marangoni, E., Frascona, V., Maggiorella, L., Abdulkarim, B., Chavaudra, N., & Bourhis, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2171 · Cited by 108 · cited 1×
“Inhibition of IGF2/IGFR1 signaling pathway markedly enhanced radiosensitivity and radiation induced apoptosis of breast cancers [96].”
BackgroundDroeser, R. A., Zlobec, I., Kilic, E., Güth, U., Heberer, M., Spagnoli, G. C., Oertli, D., & Tapia, C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-134 · Cited by 108
Liu, X., Tsang, J. Y. S., Hlaing, T., Hu, J., Ni, Y.-B., Chan, S. K., Cheung, S. Y., & Tse, G. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0029 · Cited by 107
Self-citationShen, M., Wang, J., & Ren, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00470 · Cited by 99
Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cells
Harimoto, H., Shimizu, M., Nakagawa, Y., Nakatsuka, K., Wakabayashi, A., Sakamoto, C., & Takahashi, H. (2013) · Immunology & Cell Biology · doi:10.1038/icb.2013.38 · Cited by 99
Wachstein, J., Tischer, S., Figueiredo, C., Limbourg, A., Falk, C. S., Immenschuh, S., Blasczyk, R., & Eiz‐Vesper, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051747 · Cited by 96
LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy
Rossow, L., Veitl, S., Vorlová, S., Wax, J. K., Kuhn, A. E., Maltzahn, V., Upcin, B., Karl, F., Hoffmann, H., Gätzner, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0320-2 · Cited by 95 · cited 1×
“LOX stabilizes extracellular collagen and leads to treatment resistance through changes in local signaling factors and oxygen content [100], whereas β-1 integrin is a mediator radiation resistance in breast cancer cells [101].”
BackgroundRitter, A., Friemel, A., Fornoff, F., Adjan, M., Solbach, C., Yuan, J., & Louwen, F. (2015) · Oncotarget · doi:10.18632/oncotarget.5922 · Cited by 95 · cited 1×
“Visceral, but not subcutaneous, adipocytes promote tumor proliferation and induce epithelial-to-mesenchymal transition via IL-6 and IL-8 [54].”
BackgroundArias‐Pulido, H., Cimino‐Mathews, A., Chaher, N., Qualls, C., Joste, N. E., Colpaert, C., Marotti, J. D., Foisey, M. G., Prossnitz, E. R., Emens, L. A., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4834-7 · Cited by 93
Pelekanou, V., Barlow, W. E., Nahleh, Z. A., Wasserman, B., Lo, Y.-C., von Wahlde, M.-K., Hayes, D., Hortobagyi, G. N., Gralow, J., Tripathy, D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1005 · Cited by 91
CCL1 is a major regulatory T cell attracting factor in human breast cancer
Kühnemuth, B., Piseddu, I., Wiedemann, G. M., Lauseker, M., Kühn, C., Hofmann, S., Schmoeckel, E., Endres, S., Mayr, D. C., Jeschke, U., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5117-8 · Cited by 91
Cui, Y., Li, B., Pollom, E. L., Horst, K. C., & Li, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0825 · Cited by 83
Tumour oxygenation: implications for breast cancer prognosis
Rundqvist, H., & Johnson, R. S. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12091 · Cited by 81 · cited 2×
“Oxygenation of the regional TME significantly impacts on breast tumor biology [56].”
BackgroundPoindexter, N. J., Şahin, A., Hunt, K. K., & Grimm, E. A. (2004) · Breast Cancer Research · doi:10.1186/bcr808 · Cited by 81 · cited 1×
“They also show a different cytokine profile and a lower number of CD83 + dendritic cells [67].”
BackgroundLee, H. J., Lee, J.-J., Song, I. H., Park, I. A., Kang, J. K., Yu, J. H., Ahn, J., & Gong, G. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3438-8 · Cited by 80
The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer
Aktepe, F., Kapucuoğlu, N., & Pak, I. (1996) · Histopathology · doi:10.1046/j.1365-2559.1996.d01-485.x · Cited by 78
Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer
Berry, J., Green, B. J., & Matheson, D. S. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90313-0 · Cited by 78
The metastatic microenvironment of breast cancer: Clinical implications
Coleman, R. E., Gregory, W. M., Marshall, H. C., Wilson, C., & Holen, I. (2013) · The Breast · doi:10.1016/j.breast.2013.07.010 · Cited by 76 · cited 2×
“Osteoclastic bone resorption, in turn, releases growth factors including TGF-β that stimulate cancer cell proliferation and perpetuate the osteolytic vicious cycle [7,70,71].”
BackgroundAdipocytes in the Tumour Microenvironment
Pallegar, N. K., & Christian, S. L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_1 · Cited by 73 · cited 1×
“The effects of visceral adipocytes on the breast cancer TME are especially pronounced as the breast is composed of abundant fatty tissue [55].”
BackgroundFibrotic Focus in Invasive Ductal Carcinoma: An Indicator of High Tumor Aggressiveness
Hasebe, T., Tsuda, H., Hirohashi, S., et al. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb00234.x · Cited by 72
Muliaditan, T., Opzoomer, J. W., Caron, J., Okesola, M., Kosti, P., Lall, S. K., Hemelrijck, M. V., Dazzi, F., Tutt, A. N. J., Grigoriadis, A. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2587 · Cited by 70
Jang, B., Han, W., & Kim, I. A. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.11.003 · Cited by 69
Fajardo, L. F. (1999) · Cardiovascular Radiation Medicine · doi:10.1016/s1522-1865(98)00012-2 · Cited by 68
Datta, J., Rosemblit, C., Berk, E., Showalter, L., Namjoshi, P., Mick, R., Lee, K. P., Brod, A. M., Yang, R. L., Kelz, R. R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1022301 · Cited by 66 · cited 1×
“In general, the presence of Th1 response is associated with better clinical outcome [21]; whereas the Treg can support breast cancer progression [22].”
BackgroundSeow, D. Y. B., Yeong, J. P.-S., Lim, J. X., Chia, N., Lim, J. C. T., Ong, C. C. H., Tan, P. H., & Iqbal, J. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05548-y · Cited by 62 · cited 1×
“They were also found in TLS, reflecting the development of an active anti-tumor humoral response [26].”
BackgroundCancer-Associated Fibroblasts in the Breast Tumor Microenvironment
Giorello, M. B., Borzone, F. R., Labovsky, V., Piccioni, F., & Chasseing, N. A. (2021) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-020-09475-y · Cited by 60 · cited 1×
“They are not necessarily derived from transformation of normal fibroblasts in the TME, but could origin from different tissues or precursor cells, including stellate cells, bone-marrow-derived fibrocytes, mesenchymal stem cells, or even endothelial cells, adipocytes, pericytes and smooth muscle cells [46].”
BackgroundPathak, A. P., Artemov, D., Neeman, M., & Bhujwalla, Z. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1788 · Cited by 56
Tumour radiosensitivity is associated with immune activation in solid tumours
Ström, T., Harrison, L. B., Giuliano, A. R., Schell, M. J., Eschrich, S. A., Berglund, A., Fulp, W. J., Thapa, R., Coppola, D., Kim, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.001 · Cited by 55 · cited 1×
“Increased T-cell chemoattractants, such as CXCL9 and CXCL10, indicates an immune active status after RT treatment in breast cancer patients [78].”
BackgroundBuchanan, C. F., Szot, C. S., Wilson, T. D., Akman, S., Metheny‐Barlow, L. J., Robertson, J. L., Freeman, J. W., & Rylander, M. N. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23447 · Cited by 55 · cited 1×
“Reciprocal angiogenic effects were shown by vascular endothelial cells demonstrating increased VEGF expression, endothelial proliferation, migration and organization when co-cultured with breast cancer cells [50].”
BackgroundClark, N. M., Martinez, L. M., Murdock, S. J., DeLigio, J. T., Olex, A. L., Effi, C., Dozmorov, M. G., & Bos, P. D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108482 · Cited by 55
Maiorano, E., Regan, M. M., Viale, G., Mastropasqua, M. G., Colleoni, M. A., Castiglione‐Gertsch, M., Price, K. N., Gelber, R. D., Goldhirsch, A., & Coates, A. S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0360-y · Cited by 54
Immune cell repertoires in breast cancer patients after adjuvant chemotherapy
Gustafson, C. E., Jadhav, R. R., Cao, W., Qi, Q., Pegram, M. D., Tian, L., Weyand, C. M., & Goronzy, J. J. (2020) · JCI Insight · doi:10.1172/jci.insight.134569 · Cited by 53
CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer
LEE, H., LEE, H. J., Song, I. H., Bang, W. S., Heo, S., Gong, G., & Park, I. A. (2018) · In Vivo · doi:10.21873/invivo.11415 · Cited by 53
Pathologic Evaluation of Breast Cancer after Neoadjuvant Therapy
Park, C. K., Jung, W.-H., & Koo, J. S. (2016) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2016.02.02 · Cited by 52
Béguinot, M., Dauplat, M.-M., Kwiatkowski, F., Lebouëdec, G., Tixier, L., Pomel, C., Penault-Llorca, F. M., & Radosevic‐Robin, N. (2018) · BMC Cancer · doi:10.1186/s12885-018-4013-6 · Cited by 50
Boesch, M., Onder, L., Cheng, H., Novković, M., Mörbe, U., Sopper, S., Gastl, G. A., Jochum, W., Ruhstaller, T., Knauer, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1414129 · Cited by 46 · cited 1×
“High level of CXCL12 expressed by CAF [93] via signaling through its receptor CXCR4 can support tumor cell stemness in breast cancer [94] and contribute to radioresistance.”
BackgroundStakheyeva, M., Riabov, V., Mitrofanova, I., Litviakov, N., Choynzonov, E., Cherdyntseva, N., & Kzhyshkowska, J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170714161703 · Cited by 45 · cited 1×
“The cellular components can be subdivided into local (intratumoral), regional (breast) and metastatic compartments [1,2].”
BackgroundGui, Y., Aguilar‐Mahecha, A., Krzemien, U., Hosein, A. N., Buchanan, M., Lafleur, J., Pollak, M., Ferrario, C., & Basik, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1268 · Cited by 42 · cited 1×
“Another key factor for maintenance of breast cancer stem cells, IGF2, is also expressed by breast CAF [95].”
BackgroundLarionova, I., Zavyalova, M. V., Телегина, Н. С., Buldakov, M. A., Riabov, V., Чердынцева, Н. В., & Kzhyshkowska, J. G. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.08.001 · Cited by 41
Buldakov, M. A., Zavyalova, M. V., Krakhmal, N. V., Телегина, Н. С., Vtorushin, S. V., Larionova, I., Riabov, V., Yin, S., Song, B., Чердынцева, Н. В., et al. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.09.011 · Cited by 41
Karasar, P., & Esendağlı, G. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2984-9 · Cited by 40 · cited 1×
“Among the CD4 T-cells, the type 1 helper (Th1) are induced by IFN-γ and IL-12 signals and license antigen presenting cells for effective CD8 T-cell differentiation and clonal expansion [14,15].”
Background
Metadata
- Authors
- Li, J. J., Tsang, J. Y., & Tse, G. M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-08-23
- Volume
- 13
- Issue
- 16
- Pages
- 4233
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3194062143
- Cited by
- 180
- References
- 213
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.